Skip to main content
NVDA+0.24%AAPL-0.06%GOOGL-0.61%MSFT+0.15%AMZN+0.06%TSM+0.96%SPCX+5.15%META0.00%AVGO+0.07%TSLA+0.06%SKHY+0.02%BRK-B+0.59%LLY+0.18%MU+0.29%JPM-1.01%WMT-0.55%AMD+1.65%V-1.25%XOM-3.54%JNJ+0.03%ASMLa+1.26%INTC+4.03%0700.HK-1.23%MA-0.96%ABBV-0.17%1398.HK+0.67%CSCO-2.12%CVX-2.86%ORCL+2.00%BAC-2.72%COST-0.84%KO-0.95%DELL+3.64%CAT-0.10%0005.HK+0.81%PG+0.24%HSBA.L+0.27%UNH-0.18%LRCX-0.61%AP2d+0.95%AMAT-1.37%3988.HK+0.34%GE+1.91%1816.HK-0.69%MS-1.83%NFLX-1.91%0857.HK-1.90%HD-0.99%PM-1.24%0939.HK+0.31%NZDUSD-1.76%USDJPY+1.76%AUDUSD-1.21%EURUSD-1.19%USDCHF+1.18%GBPUSD-1.11%USDTHB+1.04%CADJPY+0.92%NZDCAD-0.91%USDCAD+0.86%CHFJPY+0.71%GBPNZD+0.67%NZDCHF-0.61%GBPJPY+0.61%EURNZD+0.59%AUDNZD+0.56%EURJPY+0.55%AUDJPY+0.54%GBPTRY+0.41%EURCAD-0.37%AUDCAD-0.35%GBPHKD+0.32%USDTRY+0.31%CADCHF+0.31%GBPMXN-0.28%GBPCAD-0.27%USDILS+0.16%GBPAUD+0.09%USDCNH+0.06%EURGBP-0.05%AUDCHF-0.05%EURAUD+0.04%USDCOP-0.04%GBPCHF+0.03%USDHKD+0.02%EURCHF-0.01%NZDJPY-0.01%AUDSGD0.00%SGDJPY0.00%CHFSGD0.00%NOKJPY0.00%EURCZK0.00%NZDSGD0.00%EURNOK0.00%NZDMXN0.00%USDMXN0.00%USDNOK0.00%PLNJPY0.00%USDZAR0.00%EURPLN0.00%CHFNOK0.00%USDPLN0.00%USDSEK0.00%USDDKK0.00%EURSEK0.00%EURHKD0.00%GBPZAR0.00%AUDNOK0.00%EURCNH0.00%EURZAR0.00%EURSGD0.00%AUDDKK0.00%CHFSEK0.00%GBPSGD0.00%USDSGD0.00%EURDKK0.00%XNGUSD+0.27%USOIL-0.14%GAUUSD-0.07%XAUUSD-0.07%HG10.00%SUGAR0.00%COTTON0.00%COFFEE0.00%COCOA0.00%XPTUSD0.00%GAGUSD0.00%UKOIL0.00%BTCUSD+0.21%ETHUSD-0.15%USDTUSD+0.01%XRPUSD+0.22%SOLUSD+0.97%TRXUSDT+0.94%ZECUSDT+18.41%DOGEUSD+0.27%XMRUSDT-2.76%LINKUSD+0.07%XLMUSD+2.16%BCHUSDT+0.36%UNIUSD+0.53%LTCUSD-0.20%TONUSD+29.54%HBARUSDT-1.93%SUIUSD+2.25%TAOUSDT+0.42%AAVEUSD-2.87%DOTUSDT+6.24%ICPUSDT+0.97%ONDOUSDT+2.77%WLDUSDT+1.55%ARBUSDT+6.81%ATOMUSDT-1.54%JUPUSDT-1.19%INJUSDT-1.22%STXUSDT+1.15%FETUSDT+1.91%PYTHUSDT-1.60%TIAUSDT+2.39%SEIUSDT+1.07%IMXUSDT-1.25%GRTUSDT+1.51%OPUSDT-0.14%WIFUSDT+1.40%POLUSDT+0.62%IOTAUSDT-0.54%AXSUSDT+0.03%FARTCOINUSDT-1.04%EOSUSDT-0.91%DYDXUSDT-0.24%ORDIUSDT+2.31%GALAUSDT-2.76%NOTUSDT+1.37%RONINUSDT-2.40%NVDA+0.24%AAPL-0.06%GOOGL-0.61%MSFT+0.15%AMZN+0.06%TSM+0.96%SPCX+5.15%META0.00%AVGO+0.07%TSLA+0.06%SKHY+0.02%BRK-B+0.59%LLY+0.18%MU+0.29%JPM-1.01%WMT-0.55%AMD+1.65%V-1.25%XOM-3.54%JNJ+0.03%ASMLa+1.26%INTC+4.03%0700.HK-1.23%MA-0.96%ABBV-0.17%1398.HK+0.67%CSCO-2.12%CVX-2.86%ORCL+2.00%BAC-2.72%COST-0.84%KO-0.95%DELL+3.64%CAT-0.10%0005.HK+0.81%PG+0.24%HSBA.L+0.27%UNH-0.18%LRCX-0.61%AP2d+0.95%AMAT-1.37%3988.HK+0.34%GE+1.91%1816.HK-0.69%MS-1.83%NFLX-1.91%0857.HK-1.90%HD-0.99%PM-1.24%0939.HK+0.31%NZDUSD-1.76%USDJPY+1.76%AUDUSD-1.21%EURUSD-1.19%USDCHF+1.18%GBPUSD-1.11%USDTHB+1.04%CADJPY+0.92%NZDCAD-0.91%USDCAD+0.86%CHFJPY+0.71%GBPNZD+0.67%NZDCHF-0.61%GBPJPY+0.61%EURNZD+0.59%AUDNZD+0.56%EURJPY+0.55%AUDJPY+0.54%GBPTRY+0.41%EURCAD-0.37%AUDCAD-0.35%GBPHKD+0.32%USDTRY+0.31%CADCHF+0.31%GBPMXN-0.28%GBPCAD-0.27%USDILS+0.16%GBPAUD+0.09%USDCNH+0.06%EURGBP-0.05%AUDCHF-0.05%EURAUD+0.04%USDCOP-0.04%GBPCHF+0.03%USDHKD+0.02%EURCHF-0.01%NZDJPY-0.01%AUDSGD0.00%SGDJPY0.00%CHFSGD0.00%NOKJPY0.00%EURCZK0.00%NZDSGD0.00%EURNOK0.00%NZDMXN0.00%USDMXN0.00%USDNOK0.00%PLNJPY0.00%USDZAR0.00%EURPLN0.00%CHFNOK0.00%USDPLN0.00%USDSEK0.00%USDDKK0.00%EURSEK0.00%EURHKD0.00%GBPZAR0.00%AUDNOK0.00%EURCNH0.00%EURZAR0.00%EURSGD0.00%AUDDKK0.00%CHFSEK0.00%GBPSGD0.00%USDSGD0.00%EURDKK0.00%XNGUSD+0.27%USOIL-0.14%GAUUSD-0.07%XAUUSD-0.07%HG10.00%SUGAR0.00%COTTON0.00%COFFEE0.00%COCOA0.00%XPTUSD0.00%GAGUSD0.00%UKOIL0.00%BTCUSD+0.21%ETHUSD-0.15%USDTUSD+0.01%XRPUSD+0.22%SOLUSD+0.97%TRXUSDT+0.94%ZECUSDT+18.41%DOGEUSD+0.27%XMRUSDT-2.76%LINKUSD+0.07%XLMUSD+2.16%BCHUSDT+0.36%UNIUSD+0.53%LTCUSD-0.20%TONUSD+29.54%HBARUSDT-1.93%SUIUSD+2.25%TAOUSDT+0.42%AAVEUSD-2.87%DOTUSDT+6.24%ICPUSDT+0.97%ONDOUSDT+2.77%WLDUSDT+1.55%ARBUSDT+6.81%ATOMUSDT-1.54%JUPUSDT-1.19%INJUSDT-1.22%STXUSDT+1.15%FETUSDT+1.91%PYTHUSDT-1.60%TIAUSDT+2.39%SEIUSDT+1.07%IMXUSDT-1.25%GRTUSDT+1.51%OPUSDT-0.14%WIFUSDT+1.40%POLUSDT+0.62%IOTAUSDT-0.54%AXSUSDT+0.03%FARTCOINUSDT-1.04%EOSUSDT-0.91%DYDXUSDT-0.24%ORDIUSDT+2.31%GALAUSDT-2.76%NOTUSDT+1.37%RONINUSDT-2.40%
AR

Arvinas, Inc. (ARVN)

NASDAQHealthcare

$8.16
-$0.09 (-1.2%)
Market closed

Last close at September 16, 2026 at 20:00 UTC

Open$8.31
Day Range$8.05 - $8.32
Avg. Volume (3M)746.4K
Market Cap$526.4M
P/E Ratio42.9
52 Week Range
$6.97$14.51
Next EarningsIn 49 daysNov 4, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$249.7M100%
Gross Profitminus cost of goods$240.7M96%
Operating Incomeminus R&D and overhead$164.1M66%
Net Incomeminus taxes and the rest$169.4M68%

In plain terms: out of every $100 in revenue, Arvinas, Inc. keeps $68 as net profit.

Fundamentals & Financials

Revenue (TTM)
$316.7M
Net Income (TTM)
$9.3M
EPS (TTM)
$0.19
ROA (TTM)
1.38%
Current Ratio
7.91

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-100.0%Q1 2026-$1.1
+5.3%Q2 2026-$0.9
+789.6%Q3 2026$2.58
Next

Nov 4

in 49 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Beat +789.6%

Arvinas’ second fiscal quarter of 2026 featured negative operating cash flow, with operating cash flow at -$48.3 million, as it continued to fund development of its targeted protein degradation programs; the company reported the results on August 4, 2026. Looking ahead, next-period consensus calls for EPS of -$0.87 on revenue of $16.8 million.

View full earnings history

About Arvinas, Inc.

Arvinas, Inc. is a NASDAQ-listed biotechnology company that develops protein-degradation medicines aimed at eliminating disease-causing proteins. Its business centers on identifying, advancing, and marketing these therapies, and it generated $262.6 million of revenue in FY2025 through a model built around partnered drug development and clinical-stage candidates.

Name
Arvinas, Inc.
CEO
Randy Teel
Industry
Healthcare
Year Founded
2013
Employees
246

Today's Snapshot

AI-generated

ARVN closed 1.2% below yesterday's close, while its sector was flat. Arvinas outlined its drug pipeline and spending plans at an investor conference hosted by Morgan Stanley.

Trading Volume

Below 10d avg (911.5K)

726.1K

vs S&P 500 Today

Underperforming Market

-0.63%

Updated: September 16, 2026 at 20:06 UTC

Technical Indicators

1 Buy1 Neutral6 Sell
ARVN exhibits a clear downside bias with price trading well below short-, medium- and long-term moving averages and volume metrics aligned with distribution. Momentum measures are weak and the CCI sits deep in negative territory while RSI hovers near oversold, indicating persistent selling pressure rather than a strong reversal. ADX shows a lack of a pronounced trend, suggesting the move is not yet accompanied by firm directional conviction, and ATR implies moderate volatility relative to price. Technical takeaway: overall sell bias, driven by price below key averages and negative momentum and volume signals.
All signals
  • EMA (5 indicators)$8.65 - $9.88
    Sell
  • RSI (14)35.34
    Neutral
  • Stochastic %K (14, 3, 3)6.51
    Buy
  • MACD Level (12, 26)-0.13
    Sell
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.